| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals Inc. | IONIS-FB-LRx - (GOLDEN) | Geographic atrophy due to age-related macular degeneration (AMD) | Phase 2 | Trial Discontinued | Subcutaneous | Opthalmic |
| Ionis Pharmaceuticals Inc. | ION904 (AGT) | Uncontrolled hypertension | Phase 2 | Ongoing | Oral | Cardiology |
| Ionis Pharmaceuticals Inc. | Sapablursen | Polycythemia vera | Phase 2 | Ongoing | Subcutaneous | Hematology |
| Ionis Pharmaceuticals Inc. | Cimdelirsen (GHR) (IONIS-GHR-LRx) | Acromegaly | Phase 2 | Subcutaneous | Endocrinology | |
| Iovance Biotherapeutics Inc. | LN-145 - (IOV-LUN-202) | Anti-PD-1 therapy for advanced (unresectable or metastatic) Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Data Released | Intravenous | Oncology |
| Iovance Biotherapeutics Inc. | LN-145 and KEYTRUDA (pembrolizumab) - (IOV-COM-202) | Solid Tumors | Phase 2 | Data Released | Intravenous | Oncology |
| Iovance Biotherapeutics Inc. | LN-145 - (IOV-COM-202) | Non-small cell lung cancer (NSCLC) | Phase 2 | Data Released | Intravenous | Oncology |
| Iovance Biotherapeutics Inc. | LN-145-04 | Cervical cancer | Phase 2 | Data Released | Intravenous | Oncology |